JP2008507530A5 - - Google Patents

Download PDF

Info

Publication number
JP2008507530A5
JP2008507530A5 JP2007522657A JP2007522657A JP2008507530A5 JP 2008507530 A5 JP2008507530 A5 JP 2008507530A5 JP 2007522657 A JP2007522657 A JP 2007522657A JP 2007522657 A JP2007522657 A JP 2007522657A JP 2008507530 A5 JP2008507530 A5 JP 2008507530A5
Authority
JP
Japan
Prior art keywords
composition
agonist
ligand
cancer
tlr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007522657A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008507530A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/025602 external-priority patent/WO2006014653A1/en
Publication of JP2008507530A publication Critical patent/JP2008507530A/ja
Publication of JP2008507530A5 publication Critical patent/JP2008507530A5/ja
Pending legal-status Critical Current

Links

JP2007522657A 2004-07-20 2005-07-19 Ｔｏｌｌ様受容体を発現する腫瘍細胞におけるアポトーシスの誘導 Pending JP2008507530A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58961604P 2004-07-20 2004-07-20
PCT/US2005/025602 WO2006014653A1 (en) 2004-07-20 2005-07-19 Induction of apoptosis in toll-like receptor expressing tumor cells

Publications (2)

Publication Number Publication Date
JP2008507530A JP2008507530A (ja) 2008-03-13
JP2008507530A5 true JP2008507530A5 (OSRAM) 2008-08-07

Family

ID=35229744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007522657A Pending JP2008507530A (ja) 2004-07-20 2005-07-19 Ｔｏｌｌ様受容体を発現する腫瘍細胞におけるアポトーシスの誘導

Country Status (12)

Country Link
US (2) US20060147456A1 (OSRAM)
EP (1) EP1768699A1 (OSRAM)
JP (1) JP2008507530A (OSRAM)
KR (1) KR20070043795A (OSRAM)
CN (1) CN101018567B (OSRAM)
AT (1) ATE511859T1 (OSRAM)
AU (2) AU2005269733B2 (OSRAM)
CA (1) CA2574176A1 (OSRAM)
MX (1) MX2007000770A (OSRAM)
NO (1) NO20070945L (OSRAM)
RU (1) RU2401661C9 (OSRAM)
WO (1) WO2006014653A1 (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258712A3 (en) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
EP1613775B1 (en) * 2003-03-26 2012-08-29 Multicell Immunotherapeutics, Inc. Selected rna motifs in anti-leukemia therapy
WO2006054129A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US20120189643A1 (en) * 2004-11-30 2012-07-26 Carton Jill M Toll Like Receptor 3 Antagonists, Methods and Uses
SG170041A1 (en) 2006-03-02 2011-04-29 Agency Science Tech & Res Methods for cancer therapy and stem cell modulation
CA2652349A1 (en) 2006-05-15 2007-11-22 University Of Kentucky Research Foundation Toll-like receptor (tlr) stimulation for ocular angiogenesis and macular degeneration
EP1881080A1 (en) * 2006-07-18 2008-01-23 Institut Gustave Roussy Toll like receptor 4 dysfunction and the biological applications thereof
US20080124366A1 (en) * 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
JP5115921B2 (ja) * 2007-02-28 2013-01-09 株式会社ペルセウスプロテオミクス 腎癌の診断薬および治療薬
CA2685557A1 (en) * 2007-04-24 2008-10-30 John Wayne Cancer Institute Functional toll-like receptors (tlr) on melanocytes and melanoma cells and uses thereof
CN101909630A (zh) * 2007-11-02 2010-12-08 新加坡科技研究局 预防和治疗肿瘤的方法和化合物
GB2455204B (en) * 2007-11-28 2010-07-14 Smart Tube Inc Devices, systems and methods for the collection, stimulation, stabilization and analysis of a biological sample
JP2011518116A (ja) 2008-02-21 2011-06-23 ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション トール様受容体３拮抗薬としての超小型ｒｎａ
EP2281043B1 (en) 2008-04-25 2013-03-13 Innate Pharma Improved tlr3 agonist compositions
WO2010020590A1 (en) * 2008-08-20 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the response to anti-cancer treatment with an agonist of tlr7 or an agonist of tlr8
GB0820698D0 (en) * 2008-11-12 2008-12-17 Ludwig Inst Cancer Res Uses of immunomodulators
WO2010068680A1 (en) 2008-12-10 2010-06-17 Mount Sinai School Of Medicine Of New York University Thelper cell type 17 lineage-specific adjuvants, compositions and methods
EP2483406A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
NZ599677A (en) * 2009-12-18 2014-10-31 Bavarian Nordic As Production of ifn-lambda by conventional dendritic cells and uses thereof
KR101250419B1 (ko) * 2010-12-16 2013-04-05 강원대학교산학협력단 Ｔｌｒ 작동제를 포함하는 유방암 방사선 치료 보조제
AU2012287024A1 (en) * 2011-07-22 2014-02-20 Pawel Kalinski Tumor selective chemokine modulation
CN102652802A (zh) * 2012-04-18 2012-09-05 南京中医药大学 癌毒方在制备调控肝癌细胞TLRs／NF-κB信号转导药物中的应用
WO2014022287A1 (en) * 2012-07-29 2014-02-06 The Regents Of The University Of Colorado, A Body Corporate Antagonists of the toll-like receptor 1/2 complex
WO2015127002A1 (en) * 2014-02-19 2015-08-27 The Johns Hopkins University Compositions and methods for promoting skin regeneration and hair growth
ES2725948T3 (es) 2014-06-04 2019-09-30 Exicure Inc Suministro multivalente de inmunomoduladores mediante ácidos nucleicos esféricos liposomales para aplicaciones profilácticas o terapéuticas
CN105796594A (zh) * 2016-03-28 2016-07-27 南京大学 一种组合物在制备治疗肿瘤药物中的应用及该组合物的使用方法
CN106191238B (zh) * 2016-07-08 2020-01-10 中国医学科学院基础医学研究所 Tlr3预测肿瘤转移、评估预后和选择防治方案的应用
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
CN108295060A (zh) * 2018-04-08 2018-07-20 王长国 一种tlr7激动剂在增强cik细胞对肿瘤细胞杀伤力方面的应用
WO2020232226A1 (en) 2019-05-16 2020-11-19 The Johns Hopkins University Compositions and methods for skin rejuvenation
CN111117966A (zh) * 2020-03-02 2020-05-08 南通大学 一种利用乳酸的体外细胞培养方法
CN111579538B (zh) * 2020-04-22 2022-12-30 山东第一医科大学(山东省医学科学院) 一种利用凋亡试剂盒检测循环肿瘤细胞的方法
EP4327821A4 (en) * 2021-05-24 2025-07-23 Cha Vaccine Res Institute Co Ltd IMMUNO-ONCOLOGY THERAPEUTIC COMPOSITION USING AN ADJUVANT COMPRISING LIPOPEPTIDES AND POLY (I:C)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
CN1040504A (zh) * 1988-06-22 1990-03-21 Hem研究公司 用双链核糖核酸调节淋巴激活素抗性细胞状态
RU2136278C1 (ru) * 1998-04-07 1999-09-10 Государственный научный центр вирусологии и биотехнологии "Вектор" Противоопухолевое средство
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
AU2002360243A1 (en) * 2001-07-26 2003-05-06 Tanox, Inc. Agents that activate or inhibit toll-like receptor 9
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
WO2004047612A2 (en) * 2002-11-22 2004-06-10 Nuvelo, Inc. Methods of therapy and diagnosis
JP3810731B2 (ja) * 2002-11-29 2006-08-16 独立行政法人科学技術振興機構 哺乳動物のＴｏｌｌ様受容体３に結合する新規アダプタータンパク質およびその遺伝子

Similar Documents

Publication Publication Date Title
JP2008507530A5 (OSRAM)
EA201200560A1 (ru) Специфическая терапия, использующая интегриновые лиганды для лечения рака
Garg et al. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation
Xu et al. Targeting the HGF/c-MET pathway in advanced pancreatic cancer: A key element of treatment that limits primary tumour growth and eliminates metastasis
RU2007105987A (ru) Индукция апоптоза в опухолевых клетках, экспрессирующих toll-подобный рецептор
EA200900912A1 (ru) Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака
WO2014172376A3 (en) Markers of tumor cell response to anti-cancer therapy
MX2022006107A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
ES2422605T3 (es) Anticuerpo contra klotho-beta para utilizar en el tratamiento de tumores, cáncer o trastornos proliferativos celulares
RU2012140185A (ru) Ингибирование ангиогенеза
AR074203A1 (es) Terapia anti-angiogenesis para el tratamiento del cancer de mama. kit. uso.
EA201300246A1 (ru) Ингибиторы тирозинкиназы брутона
NZ588587A (en) Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
MY178654A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy
JP2011157399A5 (OSRAM)
EA201301106A1 (ru) ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-с]ХИНАЗОЛИНОВ
CL2011001445A1 (es) Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias
MX2009010269A (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.
TW200630105A (en) Herbal composition PHY906 and its use in chemotherapy
JP2014523398A5 (OSRAM)
EA201690321A1 (ru) Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей
EA201992513A1 (ru) Способ лечения рака груди
BR112013033544A2 (pt) dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos
AR078170A1 (es) Metodos para el tratamiento de tumores cerebrales
JP2015507020A5 (OSRAM)